Skip to main content
Erschienen in: Tumor Biology 6/2013

01.12.2013 | Research Article

Regulation of BMI1 Polycomb gene expression in histological grades of invasive ductal breast carcinomas and its correlation with hormone receptor status

verfasst von: M. V. S. Parvathi, P. Balakrishna Murthy, M. Vennila, B. V. Suresh

Erschienen in: Tumor Biology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

BMI1 is the first functional mammalian Polycomb group (PcG) proto-oncogene involved in multiple biological processes. Regulation of B cell-specific Moloney murine leukaemia virus integration site 1 (BMI1) expression with increase in histological grades of breast carcinoma in correlation with hormone receptor status was studied in 60 Indian breast cancer patient's formalin-fixed paraffin-embedded tissue blocks. Relative expression of BMI1 was studied using real-time PCR. Immunohistochemistry explained the distribution of hormone receptor markers. Correlation of BMI1 gene expression with oestrogen receptor, progesterone receptor (PR) and human epidermal growth factor receptor 2/neu status was analysed using Hex—protein docking tool. The hormone receptor expression was reduced with increasing grades of breast tumour. BMI1 gene expression was downregulated (real-time polymerase chain reaction analysis). Docking analysis explained the correlation between BMI1 and PR expression. BMI1 gene was co-regulated (down) with PR in the invasive ductal breast carcinoma with relative progression explicating it a diagnostic biomarker for ductal carcinoma of the breast.
Literatur
1.
Zurück zum Zitat Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. PNAS. 2003;100(10):5974–9.PubMedCrossRef Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. PNAS. 2003;100(10):5974–9.PubMedCrossRef
2.
Zurück zum Zitat Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.PubMedCrossRef Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.PubMedCrossRef
3.
Zurück zum Zitat Gasparini G, Pozza F. Evaluating the potential usefulness of new prognostic and predictive indicators in node negative breast cancer patients. J Natl Cancer Inst. 1993;85:1206–19.PubMedCrossRef Gasparini G, Pozza F. Evaluating the potential usefulness of new prognostic and predictive indicators in node negative breast cancer patients. J Natl Cancer Inst. 1993;85:1206–19.PubMedCrossRef
4.
Zurück zum Zitat Haupt Y, Alexander WS, Barri G, et al. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Emu-myc transgenic mice. Cell. 1991;65:753–63.PubMedCrossRef Haupt Y, Alexander WS, Barri G, et al. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Emu-myc transgenic mice. Cell. 1991;65:753–63.PubMedCrossRef
5.
Zurück zum Zitat Van der Lugt NM, Domen J, Linders K, et al. Posterior transformation, neurological, abnormalities, and severe hematopoitetic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 1994;8:757–69.PubMedCrossRef Van der Lugt NM, Domen J, Linders K, et al. Posterior transformation, neurological, abnormalities, and severe hematopoitetic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 1994;8:757–69.PubMedCrossRef
6.
Zurück zum Zitat Vonlanthen S, Heighway J, Altermatt HJ, et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 2001;84:1372–6.PubMedCrossRef Vonlanthen S, Heighway J, Altermatt HJ, et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 2001;84:1372–6.PubMedCrossRef
7.
Zurück zum Zitat Zhang F, Sui L, Xin T. Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. ExpOncol. 2008;30:70–4. Zhang F, Sui L, Xin T. Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. ExpOncol. 2008;30:70–4.
8.
Zurück zum Zitat Masashi S, Kazuhito Y, Toshiya Y, et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol. 2005;82:42–7.CrossRef Masashi S, Kazuhito Y, Toshiya Y, et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol. 2005;82:42–7.CrossRef
9.
Zurück zum Zitat Li-Bing S, Mu-Sheng Z, Wen-Ting L, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006;66:6225–32.CrossRef Li-Bing S, Mu-Sheng Z, Wen-Ting L, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006;66:6225–32.CrossRef
10.
Zurück zum Zitat Dimri GP, Martinez JL, Jacobs JJ, et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002;62:4736–45.PubMed Dimri GP, Martinez JL, Jacobs JJ, et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002;62:4736–45.PubMed
11.
Zurück zum Zitat Hongjuan C, Bo H, Tai L, et al. Bmi-1 is essential for the tumourigenicity of neuroblastoma cells. Am J Pathol. 2007;170:1370–8.CrossRef Hongjuan C, Bo H, Tai L, et al. Bmi-1 is essential for the tumourigenicity of neuroblastoma cells. Am J Pathol. 2007;170:1370–8.CrossRef
12.
Zurück zum Zitat Silva J, García V, García JM, et al. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Research. 2007;9:R55.PubMedCrossRef Silva J, García V, García JM, et al. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Research. 2007;9:R55.PubMedCrossRef
13.
Zurück zum Zitat Liu L, Andrews LG, Tollefsbol TO. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene. 2006;25:4370–5.PubMedCrossRef Liu L, Andrews LG, Tollefsbol TO. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene. 2006;25:4370–5.PubMedCrossRef
14.
Zurück zum Zitat Lee K, Adhikary G, Balasubramanian S, et al. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J Invest Dermatol. 2008;128:9–17.PubMedCrossRef Lee K, Adhikary G, Balasubramanian S, et al. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J Invest Dermatol. 2008;128:9–17.PubMedCrossRef
15.
Zurück zum Zitat Choi YJ, Choi YL, Cho EY, et al. Expression of Bmi-1 protein in tumour tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res Treat. 2009;113:83–93.PubMedCrossRef Choi YJ, Choi YL, Cho EY, et al. Expression of Bmi-1 protein in tumour tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res Treat. 2009;113:83–93.PubMedCrossRef
16.
17.
Zurück zum Zitat Sparmann A, Van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846–56.PubMedCrossRef Sparmann A, Van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846–56.PubMedCrossRef
18.
Zurück zum Zitat Van de Vijver MJ, He YD, Van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.PubMedCrossRef Van de Vijver MJ, He YD, Van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.PubMedCrossRef
19.
Zurück zum Zitat Saeki M, Kobayashi D, Tsuji N, et al. Diagnostic importance of over expression of Bmi-1 mRNA in early breast cancers. Int J Onc. 2009;35:511–5. Saeki M, Kobayashi D, Tsuji N, et al. Diagnostic importance of over expression of Bmi-1 mRNA in early breast cancers. Int J Onc. 2009;35:511–5.
20.
Zurück zum Zitat Engelsen IB, Mannelqvist M, Stefansson IM, et al. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Br J Cancer. 2008;98:1662–9.PubMedCrossRef Engelsen IB, Mannelqvist M, Stefansson IM, et al. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Br J Cancer. 2008;98:1662–9.PubMedCrossRef
21.
Zurück zum Zitat Alexandra MP, Bastiaan E, Asheeta AP, et al. Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. Curr Biol. 2008;18:1094–9.CrossRef Alexandra MP, Bastiaan E, Asheeta AP, et al. Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. Curr Biol. 2008;18:1094–9.CrossRef
22.
Zurück zum Zitat Wei-J G, Mu-Sheng Z, Ajay Y, et al. Mel-18 acts as a tumour suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res. 2007;67(11):5083–9.CrossRef Wei-J G, Mu-Sheng Z, Ajay Y, et al. Mel-18 acts as a tumour suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res. 2007;67(11):5083–9.CrossRef
Metadaten
Titel
Regulation of BMI1 Polycomb gene expression in histological grades of invasive ductal breast carcinomas and its correlation with hormone receptor status
verfasst von
M. V. S. Parvathi
P. Balakrishna Murthy
M. Vennila
B. V. Suresh
Publikationsdatum
01.12.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0965-y

Weitere Artikel der Ausgabe 6/2013

Tumor Biology 6/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.